Affinage

Showing SMARCA4 — BRG1 is a alias.

SMARCA4

SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4 · UniProt P51532

Length
1647 aa
Mass
184.6 kDa
Annotated
2026-06-10
100 papers in source corpus 44 papers cited in narrative 44 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 10/10 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SMARCA4/BRG1 is the catalytic ATPase subunit of mammalian SWI/SNF (BAF/PBAF/GBAF) chromatin-remodeling complexes that hydrolyzes ATP to reposition nucleosomes and set chromatin accessibility at enhancers, promoters, and lineage-specific regulatory elements, with its loss impairing all three complex classes and collapsing accessibility at lineage transcription-factor motifs (PMID:11238380, PMID:34561242). Acute degron-based depletion establishes BRG1 as a direct positive driver of transcription: it maintains chromatin accessibility at DNase-hypersensitive sites, nucleosome spacing at TF motifs, p300 recruitment, histone acetylation, and RNA Pol II loading at active loci (PMID:38811575). Genome-wide it co-localizes with H3K27ac at distal enhancers to support their activation while simultaneously maintaining Polycomb H3K27me3 repression of alternative-lineage genes, a dual activating/repressive function (PMID:25813539, PMID:29323272). BRG1 is targeted to chromatin by a multivalent AT-hook/bromodomain composite domain that preferentially binds AT-rich DNA and RNA, including enhancer RNAs that recruit SWI/SNF in cis to cell-type-specific enhancers and license MLL3/4, p300/CBP, and Mediator loading (PMID:28706277, PMID:32376391, PMID:38593804), and by recognition of PRMT1-deposited H4R3me2a (PMID:33853662). Locus specificity is conferred through interactions with transcription factors and cofactors including STAT3, glucocorticoid receptor (with FOXA1/GATA3 pioneer recruitment), SOX10, hemogen, HIF-1α, and PDX1/SOX9 (PMID:15286705, PMID:29792595, PMID:36305747, PMID:35297980, PMID:37198398, PMID:30010625). Its abundance is controlled by a phospho-degron axis in which CK1δ phosphorylation of Ser31/Ser35 promotes FBW7-mediated ubiquitination and degradation, opposed by OTUD6A deubiquitination, while CaMKII-dependent activity-induced phosphorylation rewires its association with NuRD and cohesin to modulate enhancer-promoter looping (PMID:30177679, PMID:35233061, PMID:34260936). BRG1 ATPase and remodeling activities are directly inhibited in vitro by noncoding RNAs Xist and Evf2, with Xist expelling BRG1 from the inactive X to reorganize TADs (PMID:26138476, PMID:30664740). Cancer missense mutations target the ATPase mechanochemical cycle to act dominant-negatively and reshape the accessible chromatin landscape toward pro-oncogenic programs such as MYC induction (PMID:29323272). SMARCA4 loss additionally provokes CDC6-dependent origin firing, uncoupling from RPA complexes and ATR-dependent replication stress, and derepresses long-terminal repeats to trigger STING/MAVS/IRF3-dependent innate immune signaling (PMID:32690724, PMID:39630912). Coffin-Siris syndrome mutations map to its RNA- and DLX1-binding domains (PMID:26138476).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 2001 High

    Established BRG1 as a bona fide ATP-dependent nucleosome-remodeling enzyme that exists in distinct multi-subunit complexes and physically links to repressive machinery, defining its core biochemical activity.

    Evidence Biochemical fractionation, in vitro nucleosome remodeling and ATPase assays, and in vitro pulldown with mSin3A components in tagged cell lines

    PMID:11238380

    Open questions at the time
    • Did not resolve how distinct complexes select different genomic targets
    • Repressive vs activating mode at endogenous loci not defined
  2. 2001 High

    Showed BRG1 ATPase activity is stimulated by an upstream kinase (LKB1) whose catalytic activity is required for BRG1-driven growth arrest, connecting remodeling to tumor-suppressor signaling.

    Evidence Domain-mapped co-IP, ATPase assay, and kinase-dead epistasis in SW13 growth-arrest assay

    PMID:11445556

    Open questions at the time
    • Phosphorylation sites on BRG1 by LKB1 not mapped
    • Mechanism of ATPase stimulation unresolved
  3. 2004 Medium

    Identified BRG1 as a transcription-factor-recruited remodeler at the p21 promoter, showing STAT3 brings BRG1 to open chromatin and load RNA Pol II, framing it as a downstream effector of signaling pathways.

    Evidence BRG1 re-expression, co-IP, ChIP, and restriction-enzyme accessibility assays in tumor cells

    PMID:14673169 PMID:15286705

    Open questions at the time
    • p53-independence of p21 activation not fully resolved
    • Generalizability of TF-directed recruitment beyond p21 untested at the time
  4. 2006 Medium

    Demonstrated BRG1 remodeling can drive non-B DNA structural transitions (Z-DNA) cooperatively required for promoter remodeling, expanding its mechanism beyond simple nucleosome sliding.

    Evidence Nucleosome positioning, Z-DNA immunoprecipitation, and transcription-inhibition assays at the CSF1 promoter

    PMID:16537901

    Open questions at the time
    • Single-promoter observation
    • Generality of Z-DNA coupling across BRG1 targets unknown
  5. 2015 Medium

    Established BRG1 as a lineage-determining remodeler in vivo, activating tissue-specific enhancers and gene programs (COUP-TFII, Pax7, mesodermal enhancers) while also maintaining Polycomb repression of alternative lineages.

    Evidence Conditional Brg1 knockouts, ChIP/ChIP-seq for H3K27ac and H3K27me3, and rescue experiments in endothelium, satellite cells, and ESC differentiation

    PMID:23406903 PMID:25813539 PMID:26036967

    Open questions at the time
    • How BRG1 sustains repressive H3K27me3 mechanistically unresolved
    • Direct vs indirect enhancer effects not fully separated
  6. 2015 Medium

    Revealed BRG1 cooperates with glucocorticoid receptor and DNA-break machinery, pre-marking GR binding sites and enabling pioneer-factor recruitment and TOP2β-mediated transient double-strand breaks for transcription.

    Evidence BRG1 knockdown with ChIP-seq for GR/FOXA1/GATA3, domain pulldown of Ku70, and TOP2β inhibition transcription assays

    PMID:26055322 PMID:29792595

    Open questions at the time
    • How BRG1 selects GR sites prior to hormone unknown
    • Physiological role of break formation vs collateral damage unresolved
  7. 2015 High

    Defined noncoding RNAs as direct inhibitors of BRG1 enzymatic activity, with Evf2 and later Xist binding and suppressing ATPase/remodeling, and Xist expelling BRG1 to reorganize X-chromosome TADs.

    Evidence MS, co-IP, in vitro ATPase and remodeling assays, and Hi-C/ChIP-seq in Xist-deletion cells

    PMID:26138476 PMID:30664740

    Open questions at the time
    • In vitro RNA inhibition is promiscuous; specificity in vivo unclear
    • Whether eRNA stimulation and lncRNA inhibition share a binding mode unresolved
  8. 2017 High

    Mapped the structural basis of BRG1 chromatin targeting, showing the AT-hook/bromodomain composite preferentially binds AT-rich DNA over histone marks, with cancer mutations altering DNA association.

    Evidence NMR, SELEX-seq, mutagenesis of the basic patch, and in vitro/ESC binding assays

    PMID:28706277 PMID:32376391

    Open questions at the time
    • Contribution of DNA binding to global targeting found minor; the dominant targeting determinant left open
    • RNA-binding role of this domain not yet defined at this stage
  9. 2017 High

    Established that cancer-associated ATPase mutations act dominant-negatively to disrupt the remodeling mechanochemical cycle and reshape the accessible chromatin landscape toward pro-oncogenic output including MYC.

    Evidence Mechanochemical analysis, ATAC-seq, and multi-mark ChIP-seq in cells expressing dominant-negative mutants

    PMID:29323272

    Open questions at the time
    • How specific loci are selectively lost vs retained unresolved
    • Link between accessibility loss and MYC induction not fully mechanistic
  10. 2018 High

    Defined a phospho-degron controlling BRG1 abundance, with CK1δ phosphorylating Ser31/Ser35 to drive SCF-FBW7 ubiquitination and degradation, coupling protein turnover to oncogenic phenotypes.

    Evidence Site-directed mutagenesis, ubiquitination and kinase assays, and co-IP with downstream E-cadherin readout

    PMID:30177679

    Open questions at the time
    • Upstream signals controlling CK1δ phosphorylation unresolved
    • Whether degradation is cell-cycle or context restricted unclear
  11. 2019 Medium

    Extended BRG1 abundance control upstream and reciprocally, with PTEN loss stabilizing BRG1 via the AKT/GSK3β/FBXW7 axis and OTUD6A deubiquitinase removing K27-linked chains to prevent degradation, both creating BRG1 dependencies in cancer.

    Evidence GEM and organoid/PDX models, protein-stability and ubiquitination assays, and catalytic-dead OTUD6A controls

    PMID:30496141 PMID:35233061

    Open questions at the time
    • Interplay between OTUD6A and FBW7 not co-defined
    • Direct E3 vs DUB balance in normal cells unquantified
  12. 2021 Medium

    Identified histone-mark- and signaling-directed recruitment of SMARCA4, including PRMT1-deposited H4R3me2a recruitment and CaMKII-dependent activity-induced phosphorylation that rewires NuRD/cohesin interactions and enhancer looping.

    Evidence ChIP-seq, co-IP, ATPase assays for the R1157W mutant, and phospho-site knockin mice with behavioral and eRNA readouts

    PMID:33853662 PMID:34260936

    Open questions at the time
    • The CaMKII-targeted phosphosite not definitively mapped
    • How H4R3me2a recruitment integrates with TF-directed targeting unresolved
  13. 2021 High

    Showed SMARCA4 loss collapses function of all three SWI/SNF subclasses (BAF/PBAF/GBAF), reducing accessibility at lineage TF motifs and driving dedifferentiation and metastasis.

    Evidence Conditional Smarca4 knockout lung cancer model with ATAC-seq, scRNA-seq, and SWI/SNF complex IP

    PMID:34561242

    Open questions at the time
    • Subclass-specific contributions to phenotype not separated
    • Cell-type dependence mechanism unresolved
  14. 2020 Medium

    Linked SMARCA4 to genome stability and replication, showing SWI/SNF physically associates with RPA and that BRG1 loss causes CDC6-dependent origin firing and ATR-dependent replication stress.

    Evidence Reciprocal co-IP with quantitative MS, DNA fiber assays, and pharmacological ATR inhibition in lung cancer cells

    PMID:32690724

    Open questions at the time
    • Direct vs transcriptional route to origin deregulation unresolved
    • Whether RPA interaction is functional at forks not demonstrated
  15. 2024 Medium

    Established that SMARCA4 loss derepresses long-terminal repeats and triggers STING/MAVS/IRF3-dependent innate immune signaling and immune infiltration, defining an immunogenic consequence of remodeler deficiency.

    Evidence SMARCA4 knockout ovarian cancer cells, RNA-seq, STING/MAVS/IRF3 knockdown epistasis, and immune flow cytometry in mouse tumors

    PMID:39630912

    Open questions at the time
    • Whether repeat derepression is direct chromatin effect unresolved
    • Type-I-IFN-independent route mechanism not fully defined
  16. 2024 Medium

    Resolved a major targeting determinant by showing the esBAF AT-hook preferentially binds eRNA, recruiting SWI/SNF in cis to cell-type-specific enhancers and licensing MLL3/4, p300/CBP, and Mediator.

    Evidence AT-hook RNA binding assays, eRNA co-IP, and coactivator ChIP-seq across differentiation stages

    PMID:38593804

    Open questions at the time
    • How eRNA stimulation reconciles with lncRNA inhibition of the same domain unresolved
    • Sequence specificity of eRNA engagement undefined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the competing inputs to BRG1 targeting and activity—TF recruitment, histone marks, AT-rich DNA, stimulatory eRNA versus inhibitory lncRNA, and phospho-regulation—are integrated to produce locus-specific accessibility decisions remains unresolved.
  • No unified model reconciling RNA stimulation vs inhibition at the AT-hook
  • Quantitative hierarchy of targeting determinants in vivo undefined
  • Structure of the full remodeler engaging a nucleosome plus RNA not resolved

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140657 ATP-dependent activity 5 GO:0003723 RNA binding 3 GO:0140096 catalytic activity, acting on a protein 3 GO:0140110 transcription regulator activity 3 GO:0003677 DNA binding 2 GO:0042393 histone binding 2
Localization
GO:0000228 nuclear chromosome 3 GO:0005634 nucleus 3
Pathway
R-HSA-1266738 Developmental Biology 4 R-HSA-1643685 Disease 4 R-HSA-4839726 Chromatin organization 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-168256 Immune System 3 R-HSA-69306 DNA Replication 1
Partners
FBW7HIF1AOTUD6APRMT1RPASOX10STAT3STK11
Complex memberships
GBAFPBAFSWI/SNF (BAF)esBAF

Evidence

Reading pass · 44 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 BRG1 (SMARCA4) fractionates into two distinct complexes that differ in activity and subunit composition; both BRG1-containing complexes and the hBrm complex can remodel nucleosomal arrays, increase restriction enzyme accessibility, and hydrolyze ATP in a DNA-dependent manner. One BRG1 complex and the hBrm complex contain mSin3A components, and BRG1, hBrm, and BAF155 directly interact with mSin3A in vitro, linking hSWI/SNF to gene repression machinery. Epitope-tagged cell lines, biochemical fractionation, nucleosome remodeling assays, ATPase assays, restriction enzyme accessibility assays, in vitro pulldown Genes & development High 11238380
2001 LKB1 (STK11) physically associates with BRG1, requiring the N-terminus of LKB1 and the helicase domain of BRG1. LKB1 stimulates the ATPase activity of BRG1. Expression of a kinase-dead LKB1 mutant blocks BRG1-induced growth arrest (flat-cell formation) in SW13 cells, demonstrating LKB1 kinase activity is required for BRG1-dependent growth arrest. Co-immunoprecipitation, domain-mapping pulldown, ATPase activity assay, cell-based growth arrest assay with kinase-dead mutant The Journal of biological chemistry High 11445556
2004 BRG1 reintroduction into BRG1-mutant breast tumor cells induces growth arrest accompanied by upregulation of CDK inhibitors p21 and p15; p21 protein is recruited to a complex with CDK2 to inhibit its activity. BRG1 associates with the p21 promoter in a p53-independent manner, suggesting direct transcriptional activation of p21. BRG1 re-expression in BRG1-null cells, microarray/RT-PCR, protein co-immunoprecipitation (p21-CDK2 complex), chromatin immunoprecipitation (ChIP) Molecular and cellular biology Medium 14673169
2004 STAT3 recruits BRG1 to the p21waf1 promoter upon cytokine stimulation; BRG1 loading results in increased chromatin accessibility at the proximal p21waf1 promoter and association of RNA Polymerase II, establishing BRG1 as a downstream effector of STAT3-mediated chromatin remodeling and transcription initiation. Co-immunoprecipitation, pulldown, chromatin immunoprecipitation (ChIP), Southern blot restriction enzyme accessibility assay Oncogene Medium 15286705
2006 BRG1 disrupts a positioned nucleosome at the TG-repeat sequence in the CSF1 promoter and induces Z-DNA formation. Both BRG1 remodeling activity and Z-DNA formation are required cooperatively for effective chromatin remodeling of the CSF1 promoter; active transcription expands but is not required to initiate Z-DNA formation. Nucleosome positioning assays, chromatin remodeling assays, Z-DNA antibody immunoprecipitation, restriction enzyme accessibility, transcription inhibition experiments Molecular and cellular biology Medium 16537901
2013 BRG1 promotes COUP-TFII expression in venous endothelial cells during murine embryogenesis by binding conserved regulatory elements within the COUP-TFII promoter and remodeling chromatin to increase promoter accessibility, thereby governing venous specification. Conditional endothelial deletion of Brg1 results in downregulated COUP-TFII and aberrant arterial marker expression on veins. Conditional knockout mouse model, ChIP, chromatin accessibility assay, immunofluorescence Development (Cambridge, England) Medium 23406903
2015 BRG1 co-localizes with H3K27ac at distal enhancers and is required for robust H3K27 acetylation at enhancers activated during mesoderm induction. BRG1 is also required to maintain Polycomb-mediated H3K27me3 repression at non-mesodermal developmental regulators, demonstrating a dual role in activating lineage-specific enhancers and maintaining repression of alternative lineage genes. ESC-based directed differentiation, Brg1 conditional knockout, ChIP-seq for H3K27ac and H3K27me3, gene expression analysis Development (Cambridge, England) Medium 25813539
2015 Evf2 lncRNA is present in a ribonucleoprotein complex with BRG1 (SMARCA4) and BAF170 (SMARCC2) in the developing mouse forebrain. Evf2 RNA directly inhibits BRG1 ATPase and chromatin remodeling activities in vitro. BRG1 interacts with DLX1 and Evf2 through distinct binding sites. RNA-mediated inhibition of BRG1 ATPase/remodeling is promiscuous in vitro. Coffin-Siris syndrome mutations localize to the BRG1 RNA-binding and DLX1-binding domains. Mass spectrometry, co-immunoprecipitation, in vitro ATPase assay, in vitro remodeling assay, nuclear colocalization imaging Development (Cambridge, England) High 26138476
2015 Brg1 controls chromatin remodeling and transcriptional activation at the Pax7 promoter in muscle satellite cells, and is required for viability and proliferation of primary myoblasts. Loss of Brg1 causes apoptosis; reintroduction of catalytically active Brg1 or Pax7 rescues the apoptotic phenotype. Conditional Brg1 deletion in primary satellite cells, ChIP, apoptosis assays, rescue with active Brg1 vs. Pax7 Journal of cellular physiology Medium 26036967
2015 BRG1 is required for glucocorticoid receptor (GR)-mediated transcription. BRG1 pre-occupies GR binding sites (GBSs) prior to hormone exposure and is required for recruitment of pioneer factors FOXA1 and GATA3 to GBSs. GR interaction with FOXA1 and GATA3 binding sites was restricted to sites pre-bound by BRG1. BRG1 knockdown in human breast cancer cells, ChIP-seq for BRG1/GR/FOXA1/GATA3, transcriptional activation assays eLife Medium 29792595
2015 Ku70 (XRCC6) associates with a BRG1 fragment encompassing the HSA and BRK domains. Ku70/86 and components of the TOP2β/PARP1 complex are required for NR-mediated SWI/SNF-dependent transcriptional activation from endogenous promoters. GR/BRG1-dependent TOP2β-mediated transient double-strand DNA breaks are required for efficient GR-stimulated transcription. BRG1 domain-fragment pulldown, ChIP, transcriptional activation assay, TOP2β inhibition experiments Molecular and cellular biology Medium 26055322
2017 SMARCA4 cancer missense mutations target conserved ATPase surfaces and disrupt the mechanochemical cycle of chromatin remodeling. Heterozygous expression of dominant-negative SMARCA4 mutants alters the open chromatin landscape at thousands of sites, causing loss of DNA accessibility at active enhancers (H3K27ac loss, H3K4me1 retained) and inducing pro-oncogenic expression changes including increased MYC expression. ATPase mechanochemical analysis, ATAC-seq, ChIP-seq (H3K27ac, H3K4me1), Polycomb ChIP-seq, gene expression analysis in cells expressing dominant-negative mutants Nature structural & molecular biology High 29323272
2017 BRG1 bromodomain (BRD) has moderate specificity for H3K14ac. Both BRG1 and hBRM BRDs have DNA-binding activity through a surface basic patch; the BRD and an adjacent AT-hook make multivalent contacts with DNA showing affinity for AT-rich elements. Histone-binding activity does not substantially contribute to nucleosome targeting in vitro, and neither BRD histone nor DNA binding contribute to global chromatin affinity of BRG1 in mouse ESCs. Biochemical binding assays, NMR, SELEX, mutagenesis of basic patch, in vitro nucleosome binding assays, mouse ESC chromatin binding Nature communications High 28706277
2017 BRG1 knockdown globally alters long-range genomic interactions and reduces TAD boundary strength, suggesting BRG1 affects nucleosome occupancy around CTCF sites at TAD boundaries and may regulate CTCF and topoisomerase complex recruitment. BRG1 knockdown, Hi-C/genome organization analysis, CTCF ChIP Nucleus (Austin, Tex.) Low 28060558
2018 SCFFBW7 ubiquitin ligase mediates BRG1 protein degradation. CK1δ phosphorylates BRG1 at Ser31/Ser35 residues to facilitate BRG1 binding to FBW7, leading to ubiquitination-mediated degradation. Stabilization of BRG1 in gastric cancer cells suppresses E-cadherin expression and promotes metastasis. Co-immunoprecipitation, site-directed mutagenesis (Ser31/Ser35), ubiquitination assay, kinase assay, E-cadherin expression analysis Nature communications High 30177679
2018 HDAC3 inhibition by entinostat decreases SMARCA4 chromatin remodeling activity, which in turn derepresses miR-27a, leading to destabilization of PAX3:FOXO1 mRNA and chemotherapy sensitization in alveolar rhabdomyosarcoma cells. HDAC3 inhibition, SMARCA4 activity assays, miR-27a expression analysis, mRNA stability assays, in vivo mouse models Science signaling Medium 30459282
2019 Xist lncRNA directly interacts with BRG1, and in vitro RNA binding inhibits nucleosome-remodeling and ATPase activities of BRG1. In cells, Xist expels BRG1 from the inactive X chromosome; Xist deletion allows selective return of BRG1 in cis, which correlates with cohesin binding and restoration of TADs and formation of de novo 'superloops'. In vitro ATPase assay, in vitro nucleosome remodeling assay, RNA-protein interaction assay, ChIP-seq, ATAC-seq, Hi-C, Xist deletion cell system Nature structural & molecular biology High 30664740
2019 PTEN loss stabilizes BRG1 protein through inhibition of the AKT/GSK3β/FBXW7 axis. Increased BRG1 in PTEN-deficient prostate cancer cells drives chromatin remodeling into a protumorigenic transcriptome, creating a synthetic lethal dependency on BRG1. Genetically engineered mouse models, organoid assays, protein stability analysis, co-immunoprecipitation, ChIP, BRG1 inhibitor treatment The Journal of clinical investigation Medium 30496141
2019 BRG1 interacts with KDM3A histone demethylase on the MUC1 promoter in a STAT1- and RelA-dependent manner, demethylating H3K9 to activate MUC1 transcription in breast cancer cells. ChIP, co-immunoprecipitation, siRNA knockdown of BRG1/KDM3A, histone modification analysis Biochemical and biophysical research communications Medium 30824191
2019 BRG1 interacts with RORγ and is recruited to the Elovl3 promoter; BRG1 also interacts with histone acetyltransferase p300 to activate Elovl3 transcription in response to androgen and TGF-β in prostate cancer cells. Co-immunoprecipitation, ChIP, siRNA knockdown, gene expression analysis Biochimica et biophysica acta. Gene regulatory mechanisms Low 31154107
2020 BRG1 (SMARCA4)-containing SWI/SNF complexes physically interact with RPA complexes, as shown by quantitative mass spectrometry and co-immunoprecipitation. BRG1 loss in lung cancer cells leads to increased origin firing mediated by CDC6 and activation of replication stress responses, creating dependency on ATR kinase. Co-immunoprecipitation, quantitative mass spectrometry, single-molecule replication fork dynamics (DNA fiber assay), pharmacological ATR inhibition Cancer research Medium 32690724
2020 Acute depletion of BRG1 (via auxin-inducible degron in knock-in mice) leads to decreased nascent RNA production and RNA Polymerase II binding at many genes, correlated with loss of BRG1 occupancy, diminished chromatin accessibility at DHSs, decreased p300 binding, and narrower nucleosome spacing at TF motifs, enhancers, and TSSs. Acute BRG1 depletion also severely compromises TSA-induced histone acetylation. Auxin-inducible degron knock-in mouse, SLAM-seq (nascent RNA), ChIP-seq (RNAPII, BRG1, p300), ATAC-seq, nucleosome mapping Nature communications High 38811575
2020 CK2 (casein kinase 2) interacts with Brg1 and phosphorylates it in a mitotic-specific manner (hyperphosphorylation during mitosis). CK2-mediated phosphorylation is associated with partitioning of Brg1 to soluble chromatin during mitosis, and this phosphorylation pattern is conserved across multiple cell types and organisms. Co-immunoprecipitation, phosphorylation/kinase assays, subcellular fractionation, cell-cycle synchronization, immunofluorescence in embryonic somites and primary myoblasts International journal of molecular sciences Medium 32019271
2021 PRMT1-mediated H4R3me2a histone modification directly recruits SMARCA4 to chromatin. SMARCA4 and PRMT1 cooperatively promote CRC progression by activating EGFR and TNS4 transcription. The SMARCA4 R1157W mutation enhances recruitment to H4R3me2a and increases SWI/SNF ATPase activity. Co-immunoprecipitation, ChIP-seq, ChIP, cell viability/migration assays, in vivo mouse CRC model, ATPase activity assay for R1157W mutant Genome medicine Medium 33853662
2021 Smarca4 loss impairs the function of all three classes of SWI/SNF complexes (BAF, PBAF, GBAF), resulting in decreased chromatin accessibility at lung lineage transcription factor motifs, ultimately driving dedifferentiated tumor states and accelerated metastasis in a cell-type-dependent manner. Conditional Smarca4 knockout mouse lung cancer model, ATAC-seq, scRNA-seq, chromatin accessibility analysis, SWI/SNF complex immunoprecipitation Cancer discovery High 34561242
2021 KDM2B interacts with Brg1 (the SWI/SNF ATPase subunit) to facilitate chromatin accessibility at the Il6 promoter specifically, and this interaction is required for IL-6 induction in macrophages/dendritic cells without altering histone demethylation at the locus. Co-immunoprecipitation, ChIP, KDM2B-conditional knockout mice, ATAC/chromatin accessibility assay Cellular & molecular immunology Medium 31197256
2021 Brg1 is required for NKp46+ ILC3 differentiation by promoting T-bet expression. Brg1 binds to both the Tbx21 and Csf2 gene loci in ILC3s, promoting active histone modifications at Tbx21 (activating T-bet) and repressive modifications at Csf2 (suppressing GM-CSF), through a cell-intrinsic mechanism that restrains intestinal inflammation. ILC3-specific Brg1 conditional KO, mixed bone marrow chimera, flow cytometry, ChIP for histone modifications at Tbx21 and Csf2 loci Mucosal immunology Medium 32612160
2021 Neuronal activity induces BRG1 phosphorylation at a serine residue sensitive to CaMKII inhibition. Phosphorylation alters BRG1 interaction with the NuRD repressor complex and cohesin, modulating enhancer-promoter looping, RNA Pol II recruitment, and enhancer RNA expression. Non-phosphorylatable BRG1 knockin mice fail to efficiently induce activity-dependent genes and show anxiety-like phenotypes. CaMKII inhibition, BRG1 phosphorylation mapping, co-immunoprecipitation (NuRD, cohesin), ChIP-seq, enhancer RNA quantification, knockin mouse behavior phenotyping Cell reports Medium 34260936
2021 SMARCA4 loss renders lung cancer cells and primary SCCOHT cells highly sensitive to inhibition of KDM6A/UTX and KDM6B/JMJD3 histone demethylases. SMARCA4-mutant cells show impaired transactivation, aberrant H3K27me3 accumulation, and significantly reduced KDM6A/KDM6B levels compared to SMARCA4-intact cells. SMARCA4-mutant cell lines, KDM6 inhibitor (GSK-J4) treatment, in vivo orthotopic tumor models, H3K27me3 ChIP, gene expression analysis Nature communications Medium 34262032
2021 OTUD6A deubiquitinase stabilizes BRG1 by erasing K27-linked polyubiquitination, thereby preventing its degradation in prostate cancer cells. OTUD6A catalytic activity (not dead-mutant) is required for this stabilization and for prostate cancer cell progression. Mass spectrometry substrate screening, co-immunoprecipitation, ubiquitination assay, catalytic dead mutant, in vivo PDX and GEM models Communications biology Medium 35233061
2022 SMARCA4/2 loss represses GLUT1 expression, reduces glucose uptake and glycolysis, and increases dependency on oxidative phosphorylation fueled by elevated glutamine import via SLC38A2. SMARCA4/2-deficient cells are sensitive to OXPHOS inhibitors and glutamine metabolism inhibitors; alanine supplementation competes with glutamine uptake via SLC38A2 and selectively kills SMARCA4/2-deficient cells. SMARCA4/2 double-knockout cells, metabolic flux assays, glucose uptake assays, SLC38A2 knockdown, in vitro and patient-derived xenograft treatment experiments Nature communications Medium 37210563
2022 Hemogen recruits SWI/SNF complex ATPase BRG1 as a coactivator to regulate nucleosome accessibility and H3K27ac enrichment at erythroid gene promoters and enhancers. BRG1 is largely dependent on hemogen to regulate chromatin accessibility at erythroid gene promoters/enhancers in mouse fetal liver, as shown by hemogen-knockout animals. Co-immunoprecipitation, ChIP-seq in WT and hemogen-KO mice, ATAC-seq, hemogen-knockout/knockin mouse models Blood Medium 35297980
2022 Brg1 loss leads to immediate increased tolerance to aneuploidy in chromosomally stable cells, and fitness recovery over time correlates with chromosome gain, demonstrating BRG1 normally suppresses aneuploidy tolerance. BRG1 deletion in chromosomally stable cell line, karyotype analysis, fitness/proliferation assays over time, proteomics Nature communications Medium 35365638
2022 SMARCA4 colocalizes with SOX10 at gene regulatory elements in diffuse midline glioma (DMG) cells; SMARCA4 chromatin binding is reduced upon depletion of SOX10 or H3.3K27M mutation. SMARCA4 controls expression of genes involved in cell growth and the extracellular matrix in DMG. ChIP-seq for SMARCA4 and SOX10, SMARCA4 KO/knockdown, H3.3K27M depletion, gene expression analysis, patient-derived xenograft models Cancer discovery Medium 36305747
2023 Brg1 interacts with lysine demethylase Kdm7aa in cardiac endothelial cells; this complex fine-tunes H3K4me3 at the promoter regions of Notch family genes, modulating Notch transcription during zebrafish heart regeneration. Dominant-negative Brg1 expression in endothelium causes abnormal Notch activation and inhibits myocardial regeneration. Co-immunoprecipitation, ChIP-seq (H3K4me3), RNA-seq, endothelium-specific dominant-negative Brg1 overexpression in zebrafish NPJ Regenerative medicine Medium 37029137
2023 Brg1 directly binds to the CXCL14 promoter and activates its transcription in hepatocytes, driving neutrophil trafficking during alcoholic liver disease. Pharmaceutical inhibition of Brg1 with PFI-3 reduces CXCL14 expression and alleviates ALD pathogenesis. Hepatocyte-specific Brg1 manipulation, RNA-seq, ChIP at CXCL14 promoter, flow cytometry, PFI-3 small molecule inhibitor treatment, in vivo ALD mouse models EMBO molecular medicine Medium 36722664
2023 The SMARCA4 R1157W mutation facilitates recruitment to PRMT1-mediated H4R3me2a chromatin and enhances the ATPase activity of the SWI/SNF complex, reinforcing transcriptional activation of EGFR and TNS4 to promote CRC cell proliferation. SMARCA4 R1157W mutant expression, ATPase activity assay, ChIP, organoid proliferation assays, xenograft models, PRMT1/SMARCA4 inhibitor combination NPJ precision oncology Medium 36922568
2023 Brg1 controls stemness and metastasis of pancreatic ductal adenocarcinoma through regulation of the hypoxia pathway. Brg1 is required for HIF-1α to bind its target genes, augmenting the hypoxia transcriptional program that maintains cancer stem-like properties and enables liver metastasis. Dual recombinase conditional Brg1 deletion in established PDAC, splenic injection/peritoneal dissemination metastasis models, ChIP for HIF-1α binding, gene expression analysis Oncogene Medium 37198398
2024 SMARCA4 loss in ovarian cancer models results in up-regulation of long-terminal RNA repeats, increased expression of interferon-stimulated genes, and up-regulation of antigen presentation machinery, dependent on STING, MAVS, and IRF3 signaling but independent of type I interferon receptor. Mouse tumors with SMARCA4 loss show increased cytotoxic T cell, NK cell, and myeloid infiltration. SMARCA4 knockout in ovarian cancer cells, RNA-seq, STING/MAVS/IRF3 knockdown epistasis, immune cell flow cytometry in mouse tumor models, BRG1 inhibitor treatment of SMARCA4-proficient cells Science advances Medium 39630912
2024 The BRG1 AT-hook of the esBAF complex preferentially binds RNA and associates with eRNA transcribed from intronic and intergenic regions. SWI/SNF is globally recruited in cis by eRNA to cell-type-specific enhancers; this facilitates recruitment of MLL3/4, p300/CBP, and Mediator to stage-specific enhancers and super-enhancers. RNA binding assays (AT-hook), eRNA co-immunoprecipitation, ChIP-seq for BRG1/MLL3/4/p300/Mediator at enhancers, cell lineage differentiation stages Molecular cell Medium 38593804
2020 NMR spectroscopy and molecular modelling of the BRG1 AT-hook/bromodomain composite domain reveal the structural basis of DNA specificity. SELEX-seq identified preferred DNA sequences for this domain; cancer mutations in the DNA-binding pocket alter the mode of DNA association. NMR spectroscopy, SELEX-seq, molecular modelling, mutagenesis of cancer-associated residues Biochimica et biophysica acta. Gene regulatory mechanisms High 32376391
2018 BRG1 binds to the Sox9 promoter in pancreatic acinar cells to regulate Sox9 expression and is critical for recruitment of upstream regulators PDX1 to the Sox9 promoter and enhancer. BRG1 loss blocks acinar-to-ductal metaplasia (ADM) and PanIN formation; Sox9 overexpression rescues the PanIN-attenuated phenotype of BRG1-deficient mice. Acinar-specific Brg1 conditional KO in Kras-mutant mice, ChIP at Sox9 promoter/enhancer, Sox9 overexpression rescue experiment, dual recombinase system for established PanIN deletion The Journal of clinical investigation High 30010625
2017 BRG1/BRM repress c-Myc expression in adult cardiomyocytes; loss of both BRG1 and BRM leads to upregulated c-MYC and progressive ventricular dysfunction with conduction defects. BRG1/BRM and c-MYC have opposite effects on cardiac conduction gene expression; BRG1/BRM occupancy is diminished at target genes in human heart failure cases. Tamoxifen-inducible cardiomyocyte-specific Brg1/Brm double KO, echocardiography, electrocardiography, inducible c-MYC overexpression, ChIP in human heart failure specimens Journal of molecular and cellular cardiology Medium 28232072
2018 SMARCAL1 and BRG1 co-localize on the promoters of ATM and ATR; downregulation of both results in transcriptional repression of ATM/ATR and override of the G2/M checkpoint. On DNA damage, phospho-ATM binds to the promoters of SMARCAL1, BRG1, ATM, and ATR, creating a feedback regulatory loop. ChIP (SMARCAL1, BRG1 at ATM/ATR promoters), siRNA knockdown, cell cycle checkpoint assays, phospho-ATM ChIP Biochimica et biophysica acta. Gene regulatory mechanisms Medium 30317028

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2020 The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 260 32709715
2001 Purification and characterization of mSin3A-containing Brg1 and hBrm chromatin remodeling complexes. Genes & development 241 11238380
2008 The BRG1 transcriptional coregulator. Nuclear receptor signaling 220 18301784
2008 Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Human mutation 216 18386774
2021 SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy. Molecular cancer therapeutics 158 34642211
2017 Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers. Nature structural & molecular biology 155 29323272
2004 Role for BRG1 in cell cycle control and tumor suppression. Molecular and cellular biology 140 14673169
2020 Clinicopathologic Characteristics of BRG1-Deficient NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 133 31988001
2005 Brg1 is required for murine neural stem cell maintenance and gliogenesis. Developmental biology 122 16330018
2014 BRG1/SMARCA4 inactivation promotes non-small cell lung cancer aggressiveness by altering chromatin organization. Cancer research 120 25115300
2021 PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling. Genome medicine 113 33853662
2001 LKB1 associates with Brg1 and is necessary for Brg1-induced growth arrest. The Journal of biological chemistry 106 11445556
2021 Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung. Cancer discovery 102 34561242
2004 Implication of BRG1 and cdk9 in the STAT3-mediated activation of the p21waf1 gene. Oncogene 98 15286705
2006 Cooperative activity of BRG1 and Z-DNA formation in chromatin remodeling. Molecular and cellular biology 89 16537901
2015 Brg1 modulates enhancer activation in mesoderm lineage commitment. Development (Cambridge, England) 87 25813539
2015 Evf2 lncRNA/BRG1/DLX1 interactions reveal RNA-dependent inhibition of chromatin remodeling. Development (Cambridge, England) 87 26138476
2021 A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers. Frontiers in immunology 85 34675941
2023 Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. Journal of the National Cancer Institute 83 37228094
2021 Recent updates in thoracic SMARCA4-deficient undifferentiated tumor. Seminars in diagnostic pathology 79 34147303
2021 SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature. Archives of pathology & laboratory medicine 75 33367658
2008 Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer. Epigenetics 75 18437052
2015 Glucocorticoid Receptor Transcriptional Activation via the BRG1-Dependent Recruitment of TOP2β and Ku70/86. Molecular and cellular biology 70 26055322
2019 Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. The Journal of clinical investigation 68 30496141
2018 SCFFBW7-mediated degradation of Brg1 suppresses gastric cancer metastasis. Nature communications 66 30177679
2017 SMARCA4-deficient Sinonasal Carcinoma. Head and neck pathology 66 28176137
2020 Recurrent Loss of SMARCA4 in Sinonasal Teratocarcinosarcoma. The American journal of surgical pathology 64 32520761
2018 The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma. Science signaling 61 30459282
2020 BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency. Cancer research 60 32690724
2018 BRG1 governs glucocorticoid receptor interactions with chromatin and pioneer factors across the genome. eLife 60 29792595
2017 DNA binding drives the association of BRG1/hBRM bromodomains with nucleosomes. Nature communications 60 28706277
2016 The BRG1 chromatin remodeling enzyme links cancer cell metabolism and proliferation. Oncotarget 59 27223259
2013 BRG1 promotes COUP-TFII expression and venous specification during embryonic vascular development. Development (Cambridge, England) 59 23406903
2019 Xist RNA antagonizes the SWI/SNF chromatin remodeler BRG1 on the inactive X chromosome. Nature structural & molecular biology 56 30664740
2019 The chromatin remodeling protein BRG1 links ELOVL3 trans-activation to prostate cancer metastasis. Biochimica et biophysica acta. Gene regulatory mechanisms 50 31154107
2018 The BRG1/SOX9 axis is critical for acinar cell-derived pancreatic tumorigenesis. The Journal of clinical investigation 50 30010625
2021 SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Nature communications 49 34262032
2017 Loss of BRG1 induces CRC cell senescence by regulating p53/p21 pathway. Cell death & disease 47 28182012
2016 SMARCA4/Brg1 coordinates genetic and epigenetic networks underlying Shh-type medulloblastoma development. Oncogene 46 27065321
2019 KDM2B promotes IL-6 production and inflammatory responses through Brg1-mediated chromatin remodeling. Cellular & molecular immunology 45 31197256
2022 SMARCA4/BRG1-Deficient Sinonasal Carcinoma. Archives of pathology & laboratory medicine 38 34871352
2021 SMARCA4/SMARCA2-deficient Carcinoma of the Esophagus and Gastroesophageal Junction. The American journal of surgical pathology 38 33027072
2020 The clinicopathological and molecular analysis of gastric cancer with altered SMARCA4 expression. Histopathology 38 32343857
2023 Targetable Brg1-CXCL14 axis contributes to alcoholic liver injury by driving neutrophil trafficking. EMBO molecular medicine 37 36722664
2023 The role of chromatin remodeler SMARCA4/BRG1 in brain cancers: a potential therapeutic target. Oncogene 37 37433987
2009 BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer. Carcinogenesis 36 19176640
2023 The SMARCA4R1157W mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer. NPJ precision oncology 35 36922568
2022 Trans-activation of eotaxin-1 by Brg1 contributes to liver regeneration. Cell death & disease 33 35614068
2023 Alanine supplementation exploits glutamine dependency induced by SMARCA4/2-loss. Nature communications 32 37210563
2022 Epigenome Programming by H3.3K27M Mutation Creates a Dependence of Pediatric Glioma on SMARCA4. Cancer discovery 32 36305747
2020 Oncogene-dependent function of BRG1 in hepatocarcinogenesis. Cell death & disease 32 32019910
2017 BRG1 promotes VEGF-A expression and angiogenesis in human colorectal cancer cells. Experimental cell research 32 28899659
2015 Brg1 Controls the Expression of Pax7 to Promote Viability and Proliferation of Mouse Primary Myoblasts. Journal of cellular physiology 31 26036967
2019 SMARCA4-Deficient Thoracic Sarcoma: A Case Report and Review of Literature. International journal of surgical pathology 30 31382829
2023 SMARCA4 Mutations in Carcinomas of the Esophagus, Esophagogastric Junction, and Stomach. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 27 37054973
2022 Molecular, clinicopathological characteristics and surgical results of resectable SMARCA4-deficient thoracic tumors. Journal of cancer research and clinical oncology 27 36121510
2024 Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods. Lung cancer (Amsterdam, Netherlands) 26 38763102
2023 Thoracic SMARCA4-deficient undifferentiated tumor. Discover oncology 26 37115343
2020 BRG1 Activates Proliferation and Transcription of Cell Cycle-Dependent Genes in Breast Cancer Cells. Cancers 26 32033115
2019 Brg1 promotes liver regeneration after partial hepatectomy via regulation of cell cycle. Scientific reports 26 30787318
2017 The connection between BRG1, CTCF and topoisomerases at TAD boundaries. Nucleus (Austin, Tex.) 26 28060558
2024 Acute depletion of BRG1 reveals its primary function as an activator of transcription. Nature communications 23 38811575
2020 Brg1 restrains the pro-inflammatory properties of ILC3s and modulates intestinal immunity. Mucosal immunology 23 32612160
2014 Expression inactivation of SMARCA4 by microRNAs in lung tumors. Human molecular genetics 23 25355421
2022 OTUD6A promotes prostate tumorigenesis via deubiquitinating Brg1 and AR. Communications biology 22 35233061
2017 BRG1 promotes hepatocarcinogenesis by regulating proliferation and invasiveness. PloS one 22 28700662
2023 Germline pathogenic SMARCA4 variants in neuroblastoma. Journal of medical genetics 21 36813544
2021 BRG1 Links TLR4 Trans-Activation to LPS-Induced SREBP1a Expression and Liver Injury. Frontiers in cell and developmental biology 21 33816466
2021 Neuronal activity-induced BRG1 phosphorylation regulates enhancer activation. Cell reports 21 34260936
2021 BRG1 knockdown inhibits proliferation through multiple cellular pathways in prostate cancer. Clinical epigenetics 20 33596994
2020 The Role of BRG1 in Antioxidant and Redox Signaling. Oxidative medicine and cellular longevity 20 33014273
2019 Brahma related gene 1 (BRG1) regulates breast cancer cell migration and invasion by activating MUC1 transcription. Biochemical and biophysical research communications 20 30824191
2017 Gfap and Osmr regulation by BRG1 and STAT3 via interchromosomal gene clustering in astrocytes. Molecular biology of the cell 20 29142070
2011 Cellular expression of Smarca4 (Brg1)-regulated genes in zebrafish retinas. BMC developmental biology 20 21756345
2024 Enhancer switching in cell lineage priming is linked to eRNA, Brg1's AT-hook, and SWI/SNF recruitment. Molecular cell 19 38593804
2021 Brahma-Related Gene-1 (BRG1) promotes the malignant phenotype of glioblastoma cells. Journal of cellular and molecular medicine 19 33528916
2003 Mutation analysis of the BRG1 gene in prostate cancer clinical samples. International journal of oncology 19 12684665
2020 CK2-Dependent Phosphorylation of the Brg1 Chromatin Remodeling Enzyme Occurs during Mitosis. International journal of molecular sciences 18 32019271
2017 BRG1 and BRM function antagonistically with c-MYC in adult cardiomyocytes to regulate conduction and contractility. Journal of molecular and cellular cardiology 18 28232072
2023 BRG1: Promoter or Suppressor of Cancer? The Outcome of BRG1's Interaction with Specific Cellular Pathways. International journal of molecular sciences 17 36769189
2022 Melatonin alleviates alcoholic liver disease via EGFR-BRG1-TERT axis regulation. Acta pharmaceutica Sinica. B 17 36815038
2020 Attenuation of epigenetic regulator SMARCA4 and ERK-ETS signaling suppresses aging-related dopaminergic degeneration. Aging cell 17 32749068
2018 Regulation of ATM and ATR by SMARCAL1 and BRG1. Biochimica et biophysica acta. Gene regulatory mechanisms 17 30317028
2022 Aneuploidy tolerance caused by BRG1 loss allows chromosome gains and recovery of fitness. Nature communications 16 35365638
2021 Brg1 Supports B Cell Proliferation and Germinal Center Formation Through Enhancer Activation. Frontiers in immunology 16 34539636
2023 Diagnosis of thoracic SMARCA4-deficient undifferentiated tumor in cytology. Cancer cytopathology 15 37278102
2023 Clinicopathological characteristics and treatment outcomes of advanced SMARCA4-deficient thoracic tumors. Cancer medicine 15 38124509
2021 BRG1 regulates lipid metabolism in hepatocellular carcinoma through the PIK3AP1/PI3K/AKT pathway by mediating GLMP expression. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 15 34158256
2020 Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer. Scientific reports 15 33230143
2017 Hypomethylation and decreased expression of BRG1 in the myocardium of patients with congenital heart disease. Birth defects research 15 28646505
2017 Brg1 inhibits E-cadherin expression in lung epithelial cells and disrupts epithelial integrity. Journal of molecular medicine (Berlin, Germany) 15 28801844
2023 Endothelial Brg1 fine-tunes Notch signaling during zebrafish heart regeneration. NPJ Regenerative medicine 14 37029137
2022 SMARCA4 biology in alveolar rhabdomyosarcoma. Oncogene 14 35094009
2022 Hemogen/BRG1 cooperativity modulates promoter and enhancer activation during erythropoiesis. Blood 14 35297980
2024 BRG1 Deficiency Promotes Cardiomyocyte Inflammation and Apoptosis by Activating the cGAS-STING Signaling in Diabetic Cardiomyopathy. Inflammation 13 38867118
2024 Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity. Science advances 13 39630912
2023 Brg1 controls stemness and metastasis of pancreatic cancer through regulating hypoxia pathway. Oncogene 13 37198398
2021 SMARCA4 (BRG1) and SMARCB1 (INI1) expression in TTF-1 negative neuroendocrine carcinomas including merkel cell carcinoma. Pathology, research and practice 13 33581550
2020 The molecular basis of selective DNA binding by the BRG1 AT-hook and bromodomain. Biochimica et biophysica acta. Gene regulatory mechanisms 13 32376391
2017 BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 13 28251496

Missed literature

Know a paper Affinage missed for SMARCA4? Flag it for the maintainers and the community.

No submissions yet.